

Prior Authorization DRUG Guidelines

Cuvposa (glycopyrrolate, oral)

Effective Date: 10/22/13

Date Developed: 9/3/13 by Albert Reeves MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20,
2/2/21, 2/1/22, 1/31/23, 2/13/24, 2/18/25

Cuvposa is a muscarinic anticholinergic agent that does not cross the blood-brain barrier.

Pre-Authorization: to reduce chronic severe drooling in patients with neurologic conditions associated with problem drooling (e.g. cerebral palsy)

Off-Label: Reduction of secretions at end of life (death rattle); Primary focal hyperhidrosis

Dosing:

1 to 2 mg once or twice daily may be a typical effective dosage range ([Ref](#)); titrate per response and tolerability; doses up to 6 to 8 mg per day in 2 or 3 divided doses have been used in some patients

NOTE: High fat food reduces the oral bioavailability

.

Adverse Reactions:

Constipation. Vomiting. Xerostomia. Heat stroke in susceptible individuals. Drowsiness. Blurred vision. Urinary retention. ~~Dry mucus membranes:~~

DRUG INTERACTIONS: anticholinergic drugs (e.g. ipratropium), drugs with anticholinergic side effects (e.g. antihistamines), cholinergic drugs (e.g. pyridostigmine [Mestinon])

REFERENCES

D'Urzo A, Ferguson GT, van Noord JA, et al, "Efficacy and Safety of Once-Daily NVA237 in Patients With Moderate-to-Severe COPD: The GLOW1 Trial," *Respir Res*, 2011, 12:156.

Kerwin E, Hébert J, Gallagher N, et al, "Efficacy and Safety of NVA237 versus Placebo and Tiotropium in Patients With COPD: The GLOW2 Study," *Eur Respir J*, 2012, 40(5):1106-14.

Sechaud R, Renard D, Zhang-Auberson L, et al, "Pharmacokinetics of Multiple Inhaled NVA237 Doses in Patients With Chronic Obstructive Pulmonary Disease (COPD)," *Int J Clin Pharmacol Ther*, 2012, 50(2):118-28.

Cuvposa (glycopyrrolate) [prescribing information]. Raleigh, NC: Merz Pharmaceuticals LLC; January 2023.

Manivannan A, Kabbani D, Levine D. Use of multiple anticholinergic medications can predispose patients to severe non-exertional hyperthermia. *BMJ Case Rep*. 2021;14(3):e239873.

Kintzel PE, Chase SL, Thomas W, Vancamp DM, Clements EA. Anticholinergic medications for managing noisy respirations in adult hospice patients. *Am J Health Syst Pharm*. 2009;66(5):458-464.

Revision History:

Date Approved by P&T Committee: 10/22/13

Date Reviewed/No Updates: 1/28/14 by C. Sanders MD

Date Approved by P&T Committee: 1/28/14

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/2/21

Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/1/22

Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/31/23
 Date Reviewed/No Updates: 2/13/24 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/13/24
 Date Reviewed/Updated: 2/18/25 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/18/25

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/18/25	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated Off-Label and dosing sections. Removed Precaution section. Added Adverse reaction section